One to watch: **CELN** Unique cancer & protate treatment with MIT, Duke University, and Massachusetts General Hospital, and Oxford University in England
CELN*** QUICK INFO FOR NEW SHAREHOLDERS.
** Has an exclusive license from MIT to provide targeted heat, non-invasive breast tumor cancer solutions. This technology has been around for over 2 decades but only now can they generate high concentrated heat to the tumor cell without burning outside tissue and more importantly , to kill the cancel cells.
PROGRESS: Phase One trials to begin on humans soon and whole process is fairly short, as their technology is NOT a drug, so does not have the lengthy testing period. Equipment, as opposed to drugs, only has 2 phases. The human results should come back within months.
** Even more timely is their OUTPATIENT treatment for Prostate problems. It will involve a related heat treatment to expand the opening so no serious operation is required. While the breast cancer treatment could be a life-saver and great news since a mastectomy could be avoided, so would a simple outpatient treatment to 50% of all men who eventually sometime in their life will experience minor or severe problems in the prostrate area.
PROGRESS: Phase I under way on humans for the prostate BPH treatment. Will be marketed outside the U.S. soon, and pre-clinical application in the U.S. soon as well they hope. The BPH treatment is ahead of the breast tumor, but both should have significant news shortly.
REMEMBER….with equipment technology, there is not the lengthy PHASE 1,2, and 3. The complete cycle time is much much shorter than drugs.
Clinical evaluations of the first generation system, which has an Investigational Device
Exemption (IDE) from the Food and Drug Administration (FDA), are underway at the
Montefiore Medical Center in Bronx, NY to demonstrate clinical efficacy in humans.
Once the clinicals are completed, Celsion intends to bring its BPH treatment system to
market abroad and apply for FDA Premarket Approval (PMA) for commercialization
in the U.S.
"Our current BPH system is positioned to notably expand the $9 billion worldwide
market for BPH treatment by encouraging more men to seek treatment, especially those
with moderate symptoms," stated CELN President and CEO Spencer Volk. "We
expect the current clinical studies to confirm the 'walk-in be treated, walk-out with total
relief' nature of our out-patient BPH system. Once the accuracy of the new temperature
sensing device is verified in animals, we will include that capability in our BPH treatment
system."
ABOUT CELSION
In addition to its BPH treatment system, under an FDA IDE Celsion is preparing to
conduct clinicals of its breast cancer treatment system to demonstrate that focused heat
alone safely and effectively ablates tumors. Celsion's research is concentrated on
designing focused heat systems to treat additional cancers.
Celsion Corporation is a research and development company dedicated to
commercializing medical treatment systems for cancer and BPH using focused heat
delivered by patented microwave technology. Clinicals and further development of the
Company's treatment systems are being conducted by leading institutions such as the
Massachusetts Institute of Technology, Massachusetts General Hospital, Montefiore
Medical Center, and Duke University.
OTHER NEWS:
COLUMBIA, Md.--(BW HealthWire)--Dec. 23, 1998--Celsion
Corporation (OTC BB: CELN) today announced that the U.S. District
Court of Maryland found in favor of the Company regarding a lawsuit
filed by Eastwell Management Services, Ltd. for $250,000
In a related decision the U.S. District Court of Maryland also
found in favor of Celsion regarding its countersuit, concluding that
Celsion is entitled to $100,000 from Eastwell Management Services
which breached the original contract between the two parties. Celsion
reported that it will pursue all legally possible avenues to collect
the $100,000 from Eastwell Management Services.
Celsion Corporation is a research and development company
dedicated to commercializing medical treatment systems for cancer and
benign prostatic hyperplasia (BPH) using focused heat delivered by
several patented microwave technologies. Clinicals and further
development of Celsion's systems are being conducted by leading
institutions such as the Massachusetts Institute of Technology,
Massachusetts General Hospital, Montefiore Medical Center, and Duke
University in the United States, and Hammersmith Hospital and Oxford
University in England.
|
